Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology t...
Saved in:
Published in | Clinical cancer research Vol. 13; no. 7; pp. 2023 - 2029 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.04.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based
assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to
use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral
blood of patients with advanced prostate cancer.
Experimental Design: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which
uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive
for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence
in situ hybridization.
Results: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories ( c = 0.99) and did not change significantly over 72 or 96 h of storage before processing ( c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including
analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor ( AR ) gene amplification, was possible for all prostate cancer patients with ≥5 CTCs.
Conclusions: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical
laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-06-2701 |